Trial Profile
A Long-term, Continued Treatment and Follow-up Study in Subjects With Hematologic Malignancies Treated With Duvelisib (IPI-145)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Sep 2023
Price :
$35
*
At a glance
- Drugs Duvelisib (Primary)
- Indications Haematological malignancies
- Focus Adverse reactions
- Sponsors Secura Bio; Verastem Oncology
- 17 Dec 2020 Status changed from active, no longer recruiting to completed.
- 28 Jul 2017 Status changed from recruiting to active, no longer recruiting.
- 21 Mar 2016 Status changed from planning to recruiting as reported by ClinicalTrials.gov.